Guanfacine
Active ingredient: Guanfacine Hydrochloride
In short: Guanfacine tablets, USP are indicated in the management of hypertension. Guanfacine tablets, USP may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
What is Guanfacine used for?
Guanfacine tablets, USP are indicated in the management of hypertension. Guanfacine tablets, USP may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
Guanfacine dosage
The recommended initial dose of guanfacine hydrochloride when given alone or in combination with another antihypertensive drug is 1 mg daily given at bedtime to minimize somnolence. If after 3 to 4 weeks of therapy 1 mg does not give a satisfactory result, a dose of 2 mg may be given, although most of the effect of guanfacine is seen at 1 mg . Higher daily doses have been used, but adverse reactions increase significantly with doses above 3 mg/day.
The frequency of rebound hypertension is low, but it can occur. When rebound occurs, it does so after 2 to 4 days, which is delayed compared with clonidine hydrochloride. This is consistent with the longer half-life of guanfacine. In most cases, after abrupt withdrawal of guanfacine, blood pressure returns to pretreatment levels slowly (within 2 to 4 days) without ill effects.
Warnings & precautions
Do not take this medicine if: Guanfacine tablets are contraindicated in patients with known hypersensitivity to guanfacine hydrochloride.
Like other antihypertensive agents, guanfacine should be used with caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease or chronic renal or hepatic failure.
Guanfacine, like other orally active central α2-adrenergic agonists, causes sedation or drowsiness, especially when beginning therapy. These symptoms are dose-related . When guanfacine is used with other centrally active depressants (such as phenothiazines, barbiturates, or benzodiazepines), the potential for additive sedative effects should be considered.
Abrupt cessation of therapy with orally active central α2-adrenergic agonists may be associated with increases (from depressed on-therapy levels) in plasma and urinary catecholamines, symptoms of “nervousness and anxiety” and, less commonly, increases in blood pressure to levels significantly greater than those prior to therapy.
Patients who receive guanfacine should be advised to exercise caution when operating dangerous machinery or driving motor vehicles until it is determined that they do not become drowsy or dizzy from the medication. Patients should be warned that their tolerance for alcohol and other CNS depressants may be diminished. Patients should be advised not to discontinue therapy abruptly.
In clinical trials, no clinically relevant laboratory test abnormalities were identified as causally related to drug during short-term treatment with guanfacine.
The potential for increased sedation when guanfacine is given with other CNS- depressant drugs should be appreciated. …
Guanfacine side effects
Adverse reactions noted with guanfacine are similar to those of other drugs of the central α2-adrenoreceptor agonist class: dry mouth, sedation (somnolence), weakness (asthenia), dizziness, constipation, and impotence. While the reactions are common, most are mild and tend to disappear on continued dosing.
Skin rash with exfoliation has been reported in a few cases; although clear cause and effect relationships to guanfacine could not be established, should a rash occur, guanfacine should be discontinued and the patient monitored appropriately.
In the dose-response monotherapy study described under
CLINICAL PHARMACOLOGY, the frequency of the most commonly observed adverse reactions showed a dose relationship from 0.5 to 3 mg as follows:
Adverse | Placebo | 0.5 mg | 1 mg | 2 mg | 3 mg
Reaction | n=59 | n=60 | n=61 | n=60 | n=59
Dry Mouth | 0% | 10% | 10% | 42% | 54%
Somnolence | 8% | 5% | 10% | 13% | 39%
Asthenia | 0% | 2% | 3% | 7% | 3%
Dizziness | 8% | 12% | 2% | 8% | 15%
Headache | 8% | 13% | 7% | 5% | 3%
Impotence | 0% | 0% | 0% | 7% | 3%
Constipation | 0% | 2% | 0% | 5% | 15%
Fatigue | 2% | 2% | 5% | 8% | 10%
The percent of patients who dropped out because of adverse reactions are shown below for each dosage group.
Placebo | 0.5 mg | 1 mg | 2 mg | 3 mg
Percent dropouts | 0% | 2% | 5% | 13% | 32%
The most common reasons for dropouts among patients who received guanfacine were dry mouth, somnolence, dizziness, fatigue, weakness, and constipation. …
About this medicine
Guanfacine hydrochloride, USP is a centrally acting antihypertensive with α2-adrenoceptor agonist properties in tablet form for oral administration.
The chemical name of guanfacine hydrochloride, USP is N-Amidino-2-(2,6-dichlorophenyl) acetamide monohydrochloride and its molecular weight is 282.55. Its structural formula is:
Guanfacine hydrochloride, USP is a white to off-white powder; sparingly soluble in water and alcohol and slightly soluble in acetone.
Each tablet, for oral administration, contains guanfacine hydrochloride, USP equivalent to 1 mg or 2 mg guanfacine. The tablets contain the following inactive ingredients:
1 mg - anhydrous lactose, FD&C Red #40 Aluminum Lake, microcrystalline cellulose, povidone, stearic acid.
2 mg - anhydrous lactose, D&C Yellow #10 Aluminum Lake, FD&C Red #40 Aluminum Lake, microcrystalline cellulose, povidone, stearic acid.
How it works: Guanfacine hydrochloride is an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α2-adrenergic receptors. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a81b956b-f004-4426-ba20-375ccf21eb71. Read the full official label on DailyMed.
Related medicines
Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone